BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23990917)

  • 1. The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women.
    Sand-Dejmek J; Ehrnström R; Berglund P; Andersson T; Ryden L
    PLoS One; 2013; 8(8):e70890. PubMed ID: 23990917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.
    Ford CE; Ekström EJ; Andersson T
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3919-24. PubMed ID: 19237581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
    Brennan DJ; Laursen H; O'Connor DP; Borgquist S; Uhlen M; Gallagher WM; Pontén F; Millikan RC; Rydén L; Jirström K
    Breast Cancer Res; 2011 Jan; 13(1):R12. PubMed ID: 21281480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERalpha negative breast cancer.
    Ford CE; Ekström EJ; Howlin J; Andersson T
    Cell Cycle; 2009 Jun; 8(12):1838-42. PubMed ID: 19448401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
    Stendahl M; Rydén L; Nordenskjöld B; Jönsson PE; Landberg G; Jirström K
    Clin Cancer Res; 2006 Aug; 12(15):4614-8. PubMed ID: 16899609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
    Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
    Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
    Colleoni M; Bonetti M; Coates AS; Castiglione-Gertsch M; Gelber RD; Price K; Rudenstam CM; Lindtner J; Collins J; Thürlimann B; Holmberg S; Veronesi A; Marini G; Goldhirsch A
    J Clin Oncol; 2000 Feb; 18(3):584-90. PubMed ID: 10653873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
    Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L;
    Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas.
    Jönsson M; Dejmek J; Bendahl PO; Andersson T
    Cancer Res; 2002 Jan; 62(2):409-16. PubMed ID: 11809689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.
    Love RR; Duc NB; Havighurst TC; Mohsin SK; Zhang Q; DeMets DL; Allred DC
    J Clin Oncol; 2003 Feb; 21(3):453-7. PubMed ID: 12560434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response.
    Kronblad A; Jirström K; Rydén L; Nordenskjöld B; Landberg G
    Int J Cancer; 2006 May; 118(10):2609-16. PubMed ID: 16381002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.